Screener
Supernus Pharmaceuticals SUPN Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Income tax expense (benefit) | (3,657) | 5,996 |
| Net loss | $(2,293) | $(11,827) |
| Loss per share | ||
| Basic | $(0.04) | $(0.21) |
| Diluted | $(0.04) | $(0.21) |
| Weighted average shares outstanding | ||
| Basic | 57,647,548 | 55,864,692 |
| Diluted | 57,647,548 | 55,864,692 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's shares (diluted)?
- Supernus Pharmaceuticals (SUPN) reported shares (diluted) of 57.6M in Q1 2026.
- How has Supernus Pharmaceuticals's shares (diluted) changed year-over-year?
- Supernus Pharmaceuticals's shares (diluted) increased by 3.2% year-over-year, from 55.9M to 57.6M.
- What is the long-term trend for Supernus Pharmaceuticals's shares (diluted)?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's shares (diluted) has grown at a 0.9% compound annual growth rate (CAGR), from 217.6M to 225.5M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Supernus Pharmaceuticals's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude